Revenue Growth
Total revenues reached EUR 127 million, marking a growth of almost 9% despite geopolitical and IXCHIQ-specific challenges.
Operating Cash Burn Reduction
Significant reduction in operating cash burn, resulting in a cash position of more than EUR 140 million.
Debt Refinancing Success
Successfully completed debt refinancing, enhancing financial flexibility with Pharmakon as a new partner.
IXIARO Sales Increase
IXIARO sales reached EUR 74.3 million, a 12.5% increase driven by sales to the U.S. Department of Defense and increased sales in Europe.
Positive Clinical Data
Reported positive safety and immunogenicity data for the Lyme vaccine candidate and positive Phase I results for the Zika vaccine candidate.